Patents by Inventor Ruby Alonso Ramirez

Ruby Alonso Ramirez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CD6 MONOCLONAL ANTIBODY USED IN THE DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS
    Publication number: 20170066835
    Abstract: The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-monoclonal antibody for the diagnosis and treatment of Autoimmune Diseases, particularly the Rheumatoid Arthritis.
    Type: Application
    Filed: November 16, 2016
    Publication date: March 9, 2017
    Inventors: JOSE ENRIQUE MONTERO CASIMIRO, ANGEL RAIMUNDO CASACO PARADA, ZAIMA MAZZORA HERRERA, RUBY ALONSO RAMIREZ, ROLANDO PEREZ RODRIGUEZ
  • PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CD6 MONOCLONAL ANTIBODY USED IN THE DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS
    Publication number: 20160024220
    Abstract: The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Autoimmune Diseases, particularly the Rheumatoid Arthritis.
    Type: Application
    Filed: April 14, 2014
    Publication date: January 28, 2016
    Applicant: CENTRO DE INMUNOLOGIA MOLECULAR
    Inventors: JOSE ENRIQUE MONTERO CASIMIRO, ANGEL RAIMUNDO CASACO PARADA, ZAIMA MAZZORA HERRERA, RUBY ALONSO RAMIREZ, ROLANDO PEREZ RODRIGUEZ
  • Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of B-chronic lymphocytic leukaemia
    Patent number: 8435521
    Abstract: The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions comprising a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions comprising a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Lymphoproliferative Syndromes and particularly the B-Cell Chronic Lymphocytic Leukemia. The essence of the invention consist in the application of a humanized Monoclonal Antibody that recognizes the CD6 antigen, the generation of pharmaceutical compositions comprising that antibody being able to induce apoptosis of malignant cells from B-Cell Chronic Lymphocytic Leukemia patients, reaching a clinical and a histological antitumor efficacy. The field of application of the present invention extends to the Oncology.
    Type: Grant
    Filed: December 24, 2007
    Date of Patent: May 7, 2013
    Assignee: Centro de Immunolgia Molecular
    Inventors: Jose Enrique Montero Casimiro, Ruby Alonso Ramirez, Rolando Perez Rodriguez
  • PHARMACEUTICAL COMPOSITIONS CAPABLE OF INDUCING APOPTOSIS IN TUMOUR CELLS, USEFUL FOR DIAGNOSIS AND TREATMENT OF B-CHRONIC LYMPHOCYTIC LEUKAEMIA
    Publication number: 20100047242
    Abstract: The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions comprising a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions comprising a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Lymphoproliferative Syndromes and particularly the B-Cell Chronic Lymphocytic Leukemia. The essence of the invention consist in the application of a humanized Monoclonal Antibody that recognizes the CD6 antigen, the generation of pharmaceutical compositions comprising that antibody being able to induce apoptosis of malignant cells from B-Cell Chronic Lymphocytic Leukemia patients, reaching a clinical and a histological antitumor efficacy. The field of application of the present invention extends to the Oncology.
    Type: Application
    Filed: December 24, 2007
    Publication date: February 25, 2010
    Inventors: Jose Enrique Montero Casimiro, Ruby Alonso Ramirez, Rolando Perez Rodriguez